David A. Siegel Pmv Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 485,700 shares of PMVP stock, worth $699,408. This represents 0.0% of its overall portfolio holdings.
Number of Shares
485,700
Previous 505,600
3.94%
Holding current value
$699,408
Previous $551,000
6.72%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PMVP
# of Institutions
61Shares Held
37.4MCall Options Held
100Put Options Held
0-
Orbimed Advisors LLC San Diego, CA6.48MShares$9.32 Million0.25% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5MShares$7.2 Million4.01% of portfolio
-
Sio Capital Management, LLC New York, NY3.74MShares$5.38 Million1.89% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO3.19MShares$4.59 Million0.07% of portfolio
-
Euclidean Capital LLC New York, NY2.63MShares$3.78 Million0.92% of portfolio
About PMV Pharmaceuticals, Inc.
- Ticker PMVP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,622,600
- Market Cap $65.7M
- Description
- PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...